Newly-released Gastro-retentive Drug Delivery Systems industry analysis report by Future Market Insights reveals that global sales of Gastro-retentive Drug Delivery Systems in 2022 were held at US$ 13.3 Billion. With a CAGR of 10.1% from 2023 to 2033, the market is expected to reach US$ 24.8 Billion by 2033. Floating Drug Delivery System is expected to be the highest revenue generating type, with a CAGR of 5% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Gastro-retentive Drug Delivery Systems Market (2023) | US$ 14 Billion |
| Global Gastro-retentive Drug Delivery Systems Market (2033) | US$ 24.8 Billion |
| Global Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 10.1% |
| USA Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 6% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Gastro-retentive Drug Delivery Systems industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Gastro-retentive Drug Delivery Systems industry increased at a CAGR of around 8.6%, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held a significant share in the global market.
Rising disease burden throughout the world and the proven efficacy of GRDDS in addressing several gastric-related disorders such as gastric ulcers, and peptic ulcers, are some of the key reasons driving the market growth. Owing to this, the gastro-retentive Drug Delivery Systems market is projected to grow at a CAGR of 10.1% over the coming 10 years.
Manufacturing systems, formulation approaches, storage systems, and technologies involved in transporting a drug to its gastrointestinal target site make gastro-retentive drug delivery global sales. Medical professionals are making use of the principles of production, rental property, locality of prescription, metabolism, and toxicity to boost the safety and potency of a drug delivery system. By making use of a gastro-retentive delivery system, illnesses can be prevented and treated using nutrients.
Large drug firms' investments to enhance gastro-retentive drug-delivery systems, along with the reduction in required doses due to enhanced bioavailability and an increase in the requirements for medications, have helped accelerate the market growth. The well-established efficacy of gastro-retentive drug delivery systems in treating a variety of stomach disorders such as peptic ulcer and gastric ulcer, as well as a growth in the incidence of H. Pylori infection, which can cause gastritis and gastric cancer, impart a significant impact on the market.
Gastro-retentive drug distribution technology has proven to be a useful way of regulating the administration of a wide range of medicinal substances while enhancing bioavailability. Advancements in controlled oral medication administration systems have been made in recent years because of technological advancements that overcome physical roadblocks such as unpredictable stomach emptying periods and short gastric residency times. By extending their dwell time in the upper GI tract, once-GRDDS can enhance oral bioavailability and therapeutic excellence.
Technological advancements for rate-controlled oral medication delivery systems are now overcoming physiological issues such as unexpected stomach emptying intervals and short gastric residency times. To address these issues, the gastro-retentive drug delivery system is designed for a longer stomach retention duration, which increases patient preference by extending the time available for medicine absorption.
Principal Consultant
North America is expected to account for significant revenue in gastro-retentive drug delivery systems market, with a market projection of US$ 10 Billion. Regional expansion is expected to be facilitated by the introduction of improved gastro-retentive medication delivery technology and the implementation of novel treatment techniques in healthcare.
GRDDS are projected to be in high demand as the prevalence of gastrointestinal disorders grows in the United States and Canada, as they lengthen medication retention time in the stomach. Demand for these devices in the region is projected to be driven by the presence of a large patient pool. Rising research and development spending in emerging markets is expected to drive regional market expansion.
Gastro-retentive Drug Delivery Systems Market in the US is expected to grow at a CAGR of 6% during the forecast period. The high prevalence of gastric cancer in the United States, as well as increasing research and development investment have contributed to the large market in the country.
The market in the United kingdom is expected to reach a valuation of US$ 1 Billion by 2033. Growing with a CAGR of 6.1% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 400 Million.
In Japan, the market is expected to grow at a CAGR of 7.2% from 2023 to 2033, reaching around US$ 1 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 500 Million during the forecast period.
The market in South Korea is expected to reach a valuation of around US$ 700 Million by 2033, growing at a CAGR of 7.3% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around US$ 400 Million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Floating Drug Delivery systems are expected to account for significant market revenue and are expected to grow at a CAGR of 5% during the forecast period. Using floating medication delivery devices is one of the most important ways for improving stomach retention and drug bioavailability. Due to this, the system has a lower bulk density than gastric fluids, it may stay buoyant in the stomach for extended periods of time without interfering with the process of gastric emptying.
This mechanism gradually and at a predetermined rate delivers the drug. When medicine is administered, the stomach's residual system is emptied. This improves segmental development by lengthening stomach retention and better control over changes in plasma medicine concentration.
Manufacturers will benefit from proprietary benefits such as industry research financing and product development agreements, which will help them contribute to the development of effective cancer diagnosis technologies. Obtaining patents and government clearances for new technology will also continue to be a key growth strategy.
The key players in the market include Ranbaxy, F. Hoffmann La Roche, Pharmacia, GlaxoSmithKline, Lupin, Pfizer, Depomed, Galanix, Sun Pharma, and Alcon, Inc.
Few of the recent developments of key Gastro-retentive Drug Delivery Systems providers are as follows:
Similarly, recent developments related to companies offering Gastro-retentive Drug Delivery Systems have been tracked by the team at Future Market Insights, which are available in the full report.
The market is expected to attain a value of US$ 14 billion in 2023.
Large drug firms' investments and technological advancements are driving the market growth.
North America is expected to offer significant opportunity for gastro-retentive drug delivery systems.
Floating drug delivery systems are highly preferred in the market.
The South Korea market is expected to expand at a CAGR of 7.3%.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type , 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type , 2023 to 2033 5.3.1. High Density System 5.3.2. Expandable Drug Delivery System 5.3.3. Bioadhesive Drug Delivery System 5.3.4. Floating Drug Delivery System 5.3.5. Other Types 5.4. Y-o-Y Growth Trend Analysis By Type , 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type , 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033 6.3.1. Tablets 6.3.2. Liquid 6.3.3. Microspheres 6.3.4. Capsule 6.3.5. Other Dosage Forms 6.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Dosage Form 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Dosage Form 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Dosage Form 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Dosage Form 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. United kingdom 11.2.1.5. Russia 11.2.1.6. BENELUX 11.2.1.7. Rest of Europe 11.2.2. By Type 11.2.3. By Dosage Form 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Dosage Form 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Rest of Asia Pacific 12.2.2. By Type 12.2.3. By Dosage Form 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Dosage Form 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Turkey 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Type 13.2.3. By Dosage Form 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Dosage Form 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Type 14.1.2.2. By Dosage Form 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Type 14.2.2.2. By Dosage Form 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Type 14.3.2.2. By Dosage Form 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Type 14.4.2.2. By Dosage Form 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Type 14.5.2.2. By Dosage Form 14.5.2.3. By Distribution Channel 14.6. Italy 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Type 14.6.2.2. By Dosage Form 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Type 14.7.2.2. By Dosage Form 14.7.2.3. By Distribution Channel 14.8. United kingdom 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Type 14.8.2.2. By Dosage Form 14.8.2.3. By Distribution Channel 14.9. Russia 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Type 14.9.2.2. By Dosage Form 14.9.2.3. By Distribution Channel 14.10. BENELUX 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Type 14.10.2.2. By Dosage Form 14.10.2.3. By Distribution Channel 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Type 14.11.2.2. By Dosage Form 14.11.2.3. By Distribution Channel 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Type 14.12.2.2. By Dosage Form 14.12.2.3. By Distribution Channel 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Type 14.13.2.2. By Dosage Form 14.13.2.3. By Distribution Channel 14.14. GCC Countries 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Type 14.14.2.2. By Dosage Form 14.14.2.3. By Distribution Channel 14.15. South Africa 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Type 14.15.2.2. By Dosage Form 14.15.2.3. By Distribution Channel 14.16. Turkey 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Type 14.16.2.2. By Dosage Form 14.16.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Type 15.3.3. By Dosage Form 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. F. Hoffmann La Roche 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Ranbaxy 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. GlaxoSmithKline 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Pharmacia 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Depomed 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Alcon, Inc. 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Lupin 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Galanix 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Sun Pharma 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Gastro-retentive Drug Delivery Systems Market
